MBX Biosciences, Inc. Common Stock
MBXNASDAQHealthcare● Active
$28.66
$-1.62(-5.34%)
Market Cap$962879857
P/E Ratio—
52W High$45.85
52W Low$9.43
MBX Biosciences, Inc. Common Stock (MBX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MBX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.51
Est. -$0.62 · +17.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
MBX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.66 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.62 | -$0.51 | +17.7% | — | — | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.64 | -$0.49 | +23.4% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.73 | -$0.63 | +13.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.77 | -$0.58 | +24.7% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.81 | -$0.71 | +12.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 17, 2025 | -$0.59 | -$0.47 | +20.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$2.72 | -$2.78 | -2.2% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.66
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.51
EPS Est.
-$0.62
EPS Surpr.
+17.7%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.49
EPS Est.
-$0.64
EPS Surpr.
+23.4%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.63
EPS Est.
-$0.73
EPS Surpr.
+13.7%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.58
EPS Est.
-$0.77
EPS Surpr.
+24.7%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.71
EPS Est.
-$0.81
EPS Surpr.
+12.3%
Revenue
—
Q1 FY2025
Mar 17, 2025Beat
EPS Actual
-$0.47
EPS Est.
-$0.59
EPS Surpr.
+20.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$2.78
EPS Est.
-$2.72
EPS Surpr.
-2.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.03 | $-1.03 | $-1.03 | 2 |
| Q3 FY2027 | $-0.94 | $-0.94 | $-0.94 | 2 |
| Q2 FY2027 | $-0.88 | $-0.88 | $-0.88 | 2 |
| Q1 FY2027 | $-1.03 | $-1.03 | $-1.03 | 2 |
| Q4 FY2026 | $-0.87 | $-0.87 | $-0.87 | 4 |
| Q3 FY2026 | $-0.82 | $-0.75 | $-0.72 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +17.7% | $32.12 | $34.71 | +8.06% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +23.4% | $28.94 | $27.95 | -3.42% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +13.7% | $22.55 | $24.74 | +9.71% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +24.7% | $11.67 | $11.13 | -4.63% |
| ▲ Q2 FY2025 | May 12, 2025 | +12.3% | $11.11 | $11.14 | +0.27% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +20.3% | $8.70 | $8.85 | +1.72% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -2.2% | $22.75 | $23.22 | +2.07% |
| — Q3 FY2024 | Aug 23, 2024 | — | No price data | $23.65 | — |
Q2 FY2026+8.06%
Report Date
May 7, 2026
EPS Beat/Miss
+17.7%
Price Before
$32.12
Price After
$34.71
Q1 FY2026-3.42%
Report Date
Mar 12, 2026
EPS Beat/Miss
+23.4%
Price Before
$28.94
Price After
$27.95
Q4 FY2025+9.71%
Report Date
Nov 6, 2025
EPS Beat/Miss
+13.7%
Price Before
$22.55
Price After
$24.74
Q3 FY2025-4.63%
Report Date
Aug 7, 2025
EPS Beat/Miss
+24.7%
Price Before
$11.67
Price After
$11.13
Q2 FY2025+0.27%
Report Date
May 12, 2025
EPS Beat/Miss
+12.3%
Price Before
$11.11
Price After
$11.14
Q1 FY2025+1.72%
Report Date
Mar 17, 2025
EPS Beat/Miss
+20.3%
Price Before
$8.70
Price After
$8.85
Q4 FY2024+2.07%
Report Date
Nov 7, 2024
EPS Beat/Miss
-2.2%
Price Before
$22.75
Price After
$23.22
Q3 FY2024—
Report Date
Aug 23, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$23.65
Avg Beat Reaction+1.95%
Avg Miss Reaction+2.07%
Beat Rate6 / 8 quarters
Largest Move+9.71% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MBX ends December
MBX Biosciences, Inc. Common Stock (MBX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.51 — beating the analyst consensus of $-0.62 by +17.7%. MBX has beaten EPS estimates for 6 consecutive quarters. The next MBX earnings date is expected around September 1, 2026.
Each quarter, investors track MBX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MBX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MBX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MBX earnings · 5 questionsMBX Biosciences, Inc. Common Stock's next earnings report is expected around September 1, 2026. MBX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MBX historically reports after market close (AMC).
MBX earnings datewhen is MBX earningsMBX next earnings datewhen does MBX report earningsMBX earnings calendar
▸ Source: FMP · MBX Biosciences, Inc. Common Stock SEC filings · US GAAP · MBX Biosciences, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026